Zobrazeno 1 - 10
of 148
pro vyhledávání: '"Stephen J. Farr"'
Autor:
PR Newswire
Publikováno v:
PR Newswire US. 06/20/2024.
Publikováno v:
Journal of Opioid Management. 11:405-415
Objectives: To assess the single-dose and steady-state pharmacokinetics of a single-entity hydrocodone extended-release (ER) formulation in patients enrolled in two separate phase 2 clinical studies . Setting: Both studies were multicenter clinical s
Publikováno v:
Clinical Pharmacokinetics. 52:907-917
Hydrocodone is a semi-synthetic narcotic analgesic and antitussive. Although hydrocodone products have been on the market for over 50 years, relatively little is known about its pharmacokinetics. Additionally, there are no published reports of popula
Autor:
Jan Lewis Brandes, Stephen J. Farr, Anthony W. Fox, Sheena K. Aurora, John F. Rothrock, Roger Cady, Judith A. Myers
Publikováno v:
Current Medical Research and Opinion. 27:2185-2191
To evaluate efficacy of, satisfaction with, and confidence in SDP (SUMAVEL DosePro *) among triptan users requiring a change in therapy. SDP is a needle-free, subcutaneous sumatriptan product that confers relief as early as 10 minutes postdose.In an
Publikováno v:
Fair Disclosure Wire (Quarterly Earnings Reports). 05/14/2019.
Publikováno v:
Pharmaceutical Research. 24:1501-1507
For a novel needle-free injection (NFI) system, the relationship between frequency of wet or incomplete injections and device-related factors and subject physiological variables was examined.A total of 26 device configurations of a single-use pre-fil
Publikováno v:
Clinical Pharmacology : Advances and Applications
Stephen J Farr,1 Cynthia Y Robinson,1 Christopher M Rubino2,3 1Zogenix, Inc., Emeryville, CA, 2Institute for Clinical Pharmacodynamics, Latham, NY, 3School of Pharmacy and Pharmaceutical Sciences, The State University of New York, University at Buffa
Publikováno v:
Fair Disclosure Wire (Quarterly Earnings Reports). 05/13/2021.
Autor:
Stephen J. Farr, Babatunde Otulana
Publikováno v:
Advanced Drug Delivery Reviews. 58:1076-1088
Pulmonary opioid delivery, on the basis of the fact that small molecular entities can be rapidly and completely absorbed from the peripheral lung, poses a unique opportunity for the treatment of severe (breakthrough) pain, which currently is treated